The latest animal models of ovarian cancer for novel drug discovery

References

• Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017 Feb;14(1):9–32.
   PubMed Web of Science ®Google Scholar
• Lengyel E. Ovarian cancer development and metastasis. Am J Pathol. 2010 Sep;177(3):1053–1064.
   PubMed Web of Science ®Google Scholar
• Scarlett UK, Conejo-Garcia JR. Modulating the tumor immune microenvironment as an ovarian cancer treatment strategy. Expert Rev Obstet Gynecol. 2012 Sep 01;7(5):413–419.
   PubMedGoogle Scholar
• Gavalas NG, Karadimou A, Dimopoulos MA, et al. Immune response in ovarian cancer: how is the immune system involved in prognosis and therapy: potential for treatment utilization. Clin Dev Immunol. 2010;2010:791603.
   PubMedGoogle Scholar
• Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch. 2012 Mar;460(3):237–249.
   PubMed Web of Science ®Google Scholar
• Kaku T, Ogawa S, Kawano Y, et al. Histological classification of ovarian cancer. Med Electron Microsc. 2003 Mar;36(1):9–17.
   PubMedGoogle Scholar
• Domcke S, Sinha R, Levine DA, et al. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun. 2013;4:2126.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature. 2011 Jun 29; 474(7353):609–615.
   PubMed Web of Science ®Google Scholar
• Bowtell DD. The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer. 2010 Nov;10(11):803–808.
   PubMed Web of Science ®Google Scholar
• Sieben NL, Macropoulos P, Roemen GM, et al. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J Pathol. 2004 Mar;202(3):336–340.
   PubMed Web of Science ®Google Scholar
• Rämer PC, Chijioke O, Meixlsperger S, et al. Mice with human immune system components as in vivo models for infections with human pathogens. Immunol Cell Biol. 2011 Mar;89(3):408–416.
   PubMed Web of Science ®Google Scholar
• Hutchinson L, Kirk R. High drug attrition rates–where are we going wrong? Nat Rev Clin Oncol. 2011 Mar 30;8(4):189–190.
   PubMed Web of Science ®Google Scholar
• Ocana A, Pandiella A, Siu LL, et al. Preclinical development of molecular-targeted agents for cancer. Nat Rev Clin Oncol. 2010 Dec 7;8(4):200–209.
   PubMed Web of Science ®Google Scholar
• Bobbs AS, Cole JM, Cowden Dahl KD. Emerging and evolving ovarian cancer animal models. Cancer Growth Metastasis. 2015;8(Suppl 1):29–36.
   PubMedGoogle Scholar
• Fong MY, Kakar SS. Ovarian cancer mouse models: a summary of current models and their limitations. J Ovarian Res. 2009 Sep 28;2(1):12.
   PubMed Web of Science ®Google Scholar
• Hasan N, Ohman AW, Dinulescu DM. The promise and challenge of ovarian cancer models. Transl Cancer Res. 2015 Feb;4(1):14–28.
   PubMed Web of Science ®Google Scholar
• Morin PJ, Weeraratna AT. Genetically-defined ovarian cancer mouse models. J Pathol. 2016 Jan;238(2):180–184.
   PubMed Web of Science ®Google Scholar
• Khanna C, Hunter K. Modeling metastasis in vivo. Carcinogenesis. 2005 Mar;26(3):513–523.
   PubMed Web of Science ®Google Scholar
• Jackson KS, Inoue K, Davis DA, et al. Three-dimensional ovarian organ culture as a tool to study normal ovarian surface epithelial wound repair. Endocrinology. 2009 Aug;150(8):3921–3926.
   PubMed Web of Science ®Google Scholar
• Zhang H, Zhang Y, Zhao H, et al. Hormonal regulation of ovarian bursa fluid in mice and involvement of aquaporins. PLoS One. 2013;8(5):e63823.
   PubMed Web of Science ®Google Scholar
• Rendi MH, Muehlenbachs A, Garcia RL, et al. Female reproductive system. Comparative anatomy and histology. Elsevier Inc; 2012. p. 253–284.
   Google Scholar
• Ng A, Barker N. Ovary and fimbrial stem cells: biology, niche and cancer origins. Nat Rev Mol Cell Biol. 2015 Oct;16(10):625–638.
   PubMed Web of Science ®Google Scholar
• Shaw TJ, Senterman MK, Dawson K, et al. Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol Ther. 2004 Dec;10(6):1032–1042.
   PubMed Web of Science ®Google Scholar
• Cordero AB, Kwon Y, Hua X, et al. In vivo imaging and therapeutic treatments in an orthotopic mouse model of ovarian cancer. J Vis Exp. 2010 Aug;17(42):1-4.
   Google Scholar
• Zhang Y, Luo L, Zheng X, et al. An advanced orthotopic ovarian cancer model in mice for therapeutic trials. Biomed Res Int. 2016;2016:2585787.
   PubMedGoogle Scholar
• Yi C, Zhang L, Zhang F, et al. Methodologies for the establishment of an orthotopic transplantation model of ovarian cancer in mice. Front Med. 2014 Mar;8(1):101–105.
   PubMed Web of Science ®Google Scholar
• Arauchi A, Yang C-H, Cho S, et al. An immunocompetent, orthotopic mouse model of epithelial ovarian cancer utilizing tissue engineered tumor cell sheets. Tissue Eng Part C Methods. 2015 Jan;21(1):23–34.
   PubMed Web of Science ®Google Scholar
• Sekine H, Shimizu T, Dobashi I, et al. Cardiac cell sheet transplantation improves damaged heart function via superior cell survival in comparison with dissociated cell injection. Tissue Eng Part A. 2011 Dec;17(23–24):2973–2980.
   PubMed Web of Science ®Google Scholar
• Yamato M, Utsumi M, Kushida A, et al. Thermo-responsive culture dishes allow the intact harvest of multilayered keratinocyte sheets without dispase by reducing temperature. Tissue Eng. 2001 Aug;7(4):473–480.
   PubMedGoogle Scholar
• Lai Y, Wei X, Lin S, et al. Current status and perspectives of patient-derived xenograft models in cancer research. J Hematol Oncol. 2017 May 12;10(1):106.
   PubMedGoogle Scholar
• Topp MD, Hartley L, Cook M, et al. Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts. Mol Oncol. 2014 May;8(3):656–668.
   PubMed Web of Science ®Google Scholar
• Whittle JR, Lewis MT, Lindeman GJ, et al. Patient-derived xenograft models of breast cancer and their predictive power. Breast Cancer Res. 2015 Feb 10;17:17.
   PubMed Web of Science ®Google Scholar
• Hidalgo M, Amant F, Biankin AV, et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 2014 Sep;4(9):998–1013.
   PubMed Web of Science ®Google Scholar
• Ben-David U, Ha G, Tseng Y-Y, et al. Patient-derived xenografts undergo mouse-specific tumor evolution. Nat Genet. 2017 Nov;49(11):1567–1575.
   PubMed Web of Science ®Google Scholar
• Vaughan S, Coward JI, Bast RC Jr., et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011 Sep 23;11(10):719–725.
   PubMed Web of Science ®Google Scholar
• Kurman RJ, Shih I-M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010 Mar;34(3):433–443.
   PubMed Web of Science ®Google Scholar
• Rygaard J, Povlsen CO. Heterotransplantation of a human malignant tumour to “Nude” mice. Acta Pathol Microbiol Scand. 1969;77(4):758–760.
   PubMedGoogle Scholar
• Fu X, Hoffman RM. Human ovarian carcinoma metastatic models constructed in nude mice by orthotopic transplantation of histologically-intact patient specimens. Anticancer Res. 1993 Mar-Apr;13(2):283–286.
   PubMed Web of Science ®Google Scholar
• Ito R, Takahashi T, Katano I, et al. Current advances in humanized mouse models. Cell Mol Immunol. 2012 May;9(3):208–214.
   PubMed Web of Science ®Google Scholar
• Paine-Murrieta GD, Taylor CW, Curtis RA, et al. Human tumor models in the severe combined immune deficient (scid) mouse. Cancer Chemother Pharmacol. 1997;40(3):209–214.
   PubMed Web of Science ®Google Scholar
• Ricci F, Bizzaro F, Cesca M, et al. Patient-derived ovarian tumor xenografts recapitulate human clinicopathology and genetic alterations. Cancer Res. 2014 Dec 1;74(23):6980–6990.
   PubMed Web of Science ®Google Scholar
• Heo EJ, Cho YJ, Cho WC, et al. Patient-derived xenograft models of epithelial ovarian cancer for preclinical studies. Cancer Res Treat. 2017 Oct;49(4):915–926.
   PubMedGoogle Scholar
• Dobbin ZC, Katre AA, Steg AD, et al. Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer. Oncotarget. 2014 Sep 30;5(18):8750–8764.
   PubMed Web of Science ®Google Scholar
• Weroha SJ, Becker MA, Enderica-Gonzalez S, et al. Tumorgrafts as in vivo surrogates for women with ovarian cancer. Clin Cancer Res. 2014 Mar 1;20(5):1288–1297.
   PubMed Web of Science ®Google Scholar
• Bondarenko G, Ugolkov A, Rohan S, et al. Patient-derived tumor xenografts are susceptible to formation of human lymphocytic tumors. Neoplasia. 2015 Sep;17(9):735–741.
   PubMed Web of Science ®Google Scholar
• Butler KA, Hou X, Becker MA, et al. Prevention of human lymphoproliferative tumor formation in ovarian cancer patient-derived xenografts. Neoplasia. 2017 Aug;19(8):628–636.
   PubMed Web of Science ®Google Scholar
• Bankert RB, Balu-Iyer SV, Odunsi K, et al. Humanized mouse model of ovarian cancer recapitulates patient solid tumor progression, ascites formation, and metastasis. PLoS One. 2011;6(9):e24420.
   PubMed Web of Science ®Google Scholar
• Koneru M, Purdon TJ, Spriggs D, et al. IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. Oncoimmunology. 2015 Mar;4(3):e994446.
   PubMed Web of Science ®Google Scholar
• Chang D-K, Peterson E, Sun J, et al. Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model. Oncoimmunology. 2016 Mar;5(3):e1090075.
   PubMed Web of Science ®Google Scholar
• Wang W, Kryczek I, Dostál L, et al. Effector T cells abrogate stroma-mediated chemoresistance in ovarian cancer. Cell. 2016 May 19;165(5):1092–1105.
   PubMed Web of Science ®Google Scholar
• Duraiswamy J, Kaluza KM, Freeman GJ, et al. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res. 2013 Jun 15;73(12):3591–3603.
   PubMed Web of Science ®Google Scholar
• Gaillard SL, Secord AA, Monk B. The role of immune checkpoint inhibition in the treatment of ovarian cancer. Gynecol Oncol Res Pract. 2016;3:11.
   PubMedGoogle Scholar
• Holub M, Rossmann P, Tlaskalova H, et al. Thymus rudiment of the athymic nude mouse. Nature. 1975 Aug 07;256(5517):491–493.
   PubMed Web of Science ®Google Scholar
• Maykel J, Liu JH, Li H, et al. NOD-scidIl2rg (tm1Wjl) and NOD-Rag1 (null) Il2rg (tm1Wjl): a model for stromal cell-tumor cell interaction for human colon cancer. Dig Dis Sci. 2014 Jun;59(6):1169–1179.
   PubMed Web of Science ®Google Scholar
• Pearson T, Greiner DL, Shultz LD. Creation of “humanized” mice to study human immunity. Curr Protoc Immunol. 2008 May. Chapter 15: Unit15 21:1-28.
   PubMedGoogle Scholar
• Laboratory TJ. Onco-Hu models: humanized NSG and NSG-SGM3 mice for immuno-oncology. Available from: http://jackson.jax.org/rs/444-BUH-304/images/LT0074_US_Immuno_Oncology_Whitepaper_WEB.pdf
   Google Scholar
• Laboratory TJ. Inventor non-HLA matched humanized NSG mouse model with patient-derived xenograft. 2016. Publication number: WO 2016209865 A1
   Google Scholar
• Wang M, Yao LC, Cheng M, et al. Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy. Faseb J. 2017 Nov 16.
   Google Scholar
• Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7875–7880.
   PubMed Web of Science ®Google Scholar
• Colvin EK. Tumor-associated macrophages contribute to tumor progression in ovarian cancer. Front Oncol. 2014;4:137.
   PubMedGoogle Scholar
• Knutson KL, Maurer MJ, Preston CC, et al. Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer. Cancer Immunol Immunother. 2015 Dec;64(12):1495–1504.
   PubMed Web of Science ®Google Scholar
• Chung W, Eum HH, Lee HO, et al. Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer. Nat Commun. 2017 May 5;8:15081.
   PubMed Web of Science ®Google Scholar
• Kargl J, Busch SE, Yang GH, et al. Neutrophils dominate the immune cell composition in non-small cell lung cancer. Nat Commun. 2017 Feb;1(8):14381.
   Google Scholar
• Tsujikawa T, Kumar S, Borkar RN, et al. Quantitative multiplex immunohistochemistry reveals myeloid-inflamed tumor-immune complexity associated with poor prognosis. Cell Rep. 2017 Apr 4;19(1):203–217.
   PubMed Web of Science ®Google Scholar